The role of herpes and human papillomavirus infection in prostate and bladder carcinogenesis
L. M. Mikhaleva,
A. A. Kamalov,
G. G. Maryin,
V. K. Karpov,
E. P. Akopyan,
O. A. Osmanov,
V. V. Pechnikova https://doi.org/10.20538/1682-0363-2021-4-153-161
Abstract
Human papillomavirus (HPV) is a small epithelial, non-enveloped, double-stranded DNA virus that belongs to the Papillomaviridae family. HPV infection is one of the most common sexually transmitted infections, and certain types of HPV are known to be carcinogenic to humans. According to the scientific literature, there is reliable information about the role of highly oncogenic HPV types in the development of cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancer.
Currently, a relevant and promising research area is the study of the role of HPV infection in prostate cancer (PC) and bladder cancer (BC), but scientific data on the potential pathogenetic relationship between these phenomena remain contradictory. An in-depth study of the question how herpes and human papillomavirus affect the origin of malignant tumors of the prostate and bladder, as well as the course of these diseases, and the prognosis of their development can become a source of information for development of new approaches to their diagnosis, prevention, and monitoring of morbidity. This literature review analyzes the results of modern studies on the role of oncogenic HPV types in the carcinogenesis of PC and BC.
About the Authors
L. M. Mikhaleva
A.P. Avtsyn Research Institute of Human Morphology;
City Clinical Hospital No. 31
Russian Federation
Russian Federation
3, Tsyrupy Str., Moscow, 117418;
42, Lobachevskogo Str., Moscow, 119415
A. A. Kamalov
Lomonosov Moscow State University;
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
1, Leninskiye Gory, Moscow, 119991;
3–14, Solyanka Str., Moscow, 109240
G. G. Maryin
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
3–14, Solyanka Str., Moscow, 109240
V. K. Karpov
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
3–14, Solyanka Str., Moscow, 109240
E. P. Akopyan
A.P. Avtsyn Research Institute of Human Morphology;
City Clinical Hospital No. 31
Russian Federation
Russian Federation
3, Tsyrupy Str., Moscow, 117418;
42, Lobachevskogo Str., Moscow, 119415
O. A. Osmanov
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
3–14, Solyanka Str., Moscow, 109240
V. V. Pechnikova
A.P. Avtsyn Research Institute of Human Morphology;
City Clinical Hospital No. 31
Russian Federation
Russian Federation
3, Tsyrupy Str., Moscow, 117418;
42, Lobachevskogo Str., Moscow, 119415
References
1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015; 136 (5): e359–386. DOI: 10.1002/ijc.29210.
2. The Global Cancer Observatory. URL: http://gco.iarc.fr
3. Прилепская Е.А., Мальцев Е.Г., Колонтарев К.Б., Говоров А.В., Раснер П.П., Васильев А.О., Садченко А.В., Дьяков В.Я., Пушкарь Д.Ю. Сравнительный анализ функциональных и онкологических результатов радикальной простатэктомии – позадилонной, лапароскопической и робот-ассистированной. Онкоурология. 2015; 11 (4): 54–58. DOI: 10.17650/1726-9776-2015-11-4-54-58.
4. Schröder F.H., Roobol M.J. Prostate cancer epidemic in sight? Eur. Urol. 2012; 61 (6): 1093–1095. DOI: 10.1016/j.eururo.2012.03.019.
5. Злокачественные новообразования в России в 2018 году; под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019: 250.
6. Delongchamps N.B., Singh A., Haas G.P. The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006; 13 (3): 158–168. DOI: 10.1177/107327480601300302.
7. Сиразиев А.М., Хасанова Г.Р., Ульянин М.Ю. Факторы риска рака предстательной железы. Медицинский альманах. 2019; 3-4 (60): 110–114. DOI: 10.21145/2499-9954-2019-3-110-114.
8. Chen C.J., Hsu W.L., Yang H.I., Lee M.H., Chen H.C., Chien Y.C., You S.L. Epidemiology of virus infection and human cancer. Recent Results Cancer Res. 2014; 93: 11–32. DOI: 10.1007/978-3-642-38965-8_2.
9. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 2002; 420 (6917): 8607. DOI: 10.1038/nature01322.
10. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008; 454 (7203): 436–444. DOI: 10.1038/nature07205.
11. Heidegger I., Borena W., Pichler R. The role of human papilloma virus in urological malignancies. Anticancer Res. 2015; 35 (5): 2513–2519.
12. Gillison M.L., Chaturvedi A.K., Anderson W.F., Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J. Clin. Oncol. 2015; 33 (29): 3235–3242. DOI: 10.1200/JCO.2015.61.6995.
13. Gao G., Smith D.I. Human papillomavirus and the development of different cancers. Cytogenet. Genome Res. 2016; 150 (3-4): 185–193. DOI: 10.1159/000458166.
14. Stratton K.L., Culkin D.J. A contemporary review of HPV and penile cancer. Oncology (Williston Park). 2016; 30 (3): 245–249.
15. Nelson V.M., Benson A.B. 3rd. Epidemiology of anal canal cancer. Surg. Oncol. Clin. N. Am. 2017 26 (1): 9–15. DOI: 10.1016/j.soc.2016.07.001.
16. Волгарева Г.М., Ермилова В.Д. Обнаружение онкогена Е7 вируса папилломы человека 18-го типа у больных раком предстательной железы. Российский биотерапевтический журнал. 2019; 18 (1): 37–41. DOI: 10.17650/1726-9784-2019-18-1-37-41
17. Jiang J., Li J., Yunxia Z., Zhu H., Liu J., Pumill C. The role of prostatitis in prostate cancer: meta-analysis. PLoS One. 2013; 8 (12): e85179. DOI: 10.1371/journal.pone.0085179.
18. Sfanos K.S., Isaacs W.B., De Marzo A.M. Infections and inflammation in prostate cancer. Am. J. Clin. Exp. Urol. 2013; 1 (1): 3–11.
19. Caini S., Gandini S., Dudas M., Bremer V., Severi E., Gherasim A. Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol. 2014; 38 (4): 329–338. DOI: 10.1016/j.canep.2014.06.002.
20. Taverna G., Pedretti E., Di Caro G., Borroni E.M., Marchesi F., Grizzi F. Inflammation and prostate cancer: friends or foe? Inflamm. Res. 2015; 64 (5): 275–286. DOI: 10.1007/s00011-015-0812-2.
21. McNicol P.J., Dodd J.G. Detection of human papillomavirus DNA in prostate gland tissue by using the polymerase chain reaction amplification assay. J. Clin. Microbiol. 1990; 28 (3): 409–412. DOI: 10.1128/JCM.28.3.409-412.1990.
22. Волгарева Г.М., Ермилова В.Д., Хачатурян А.В., Татарский В.В., Матвеев В.Б., Павлова Л.С. Детекция с помощью полимеразной цепной реакции генетического материала вируса папилломы человека 16-го типа в операционном материале от больных раком предстательной железы. Онкоурология. 2017; 3 (4): 51–54. DOI: 10.17650/1726-9776-2017-13-4-51-54
23. Atashafrooz F., Rokhbakhsh-Zamin F. Frequency and type distribution of human papilloma virus in patients with prostate cancer, Kerman, Southeast of Iran. Asian Pac. J. Cancer Prev. 2016; 17 (8): 3953–3958.
24. Huang L., Wu M.G., He J., Wei Z.S., Lü W.X., Song X.J., Zhang Y., Wu S.X., Yin Y.L., Fan Y.Y. Correlation of highrisk HPV 16/18 infections with prostate cancer. Zhonghua Nan Ke Xue. 2016; 22 (6): 501–505. PMID: 28963837.
25. Glenn W.K., Ngan C.C., Amos T.G., Edwards R.J., Swift J., Lutze-Mann L., Shang F., Whitaker N.J., Lawson J.S. High risk human papilloma viruses (HPVs) are present in benign prostate tissues before development of HPV associated prostate cancer. Infect Agent Cancer. 2017; 12: 46. DOI: 10.1186/s13027-017-0157-2.
26. Medel-Flores O., Valenzuela-Rodríguez V.A., Ocadiz-Delgado R., Castro-Muñoz L.J., Hernández-Leyva S., Lara-Hernández G., Silva-Escobedo J.G., Vidal P.G., Sánchez-Monroy V. Association between HPV infection and prostate cancer in a Mexican population. Genet. Mol. Biol. 2018; 41 (4): 781–789. DOI: 10.1590/1678-4685-GMB-2017-0331.
27. Russo G.I., Calogero A.E., C21ondorelli R.A., Scalia G., Morgia G., La Vignera S. Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis. Aging Male. 2020; 23 (2): 132–138. DOI: 10.1080/13685538.2018.1455178.
28. Moghoofei M., Keshavarz M., Ghorbani S. et al. Association between human papillomavirus infection and prostate cancer: A global systematic review and meta-analysis. Asia Pac. J. Clin. Oncol. 2019; 15 (5): e59–67. DOI: 10.1111/AJCO.13124.
29. Jørgensen K.R., Jensen J.B. Human papillomavirus and urinary bladder cancer revisited. APMIS. 2020 Feb.; 128 (2): 72–79. DOI: 10.1111/apm.13016.
30. National clinical guidelines for treatment of bladder tumors in Denmark. Denmark: Danish Bladder Cancer Group (DaBlaCa); 2017. URL: https://www.sundhed.dk/content/cms/86/15686_dablacadata_-aarsrapport_2017_v2_endelig.pdf
31. Huang W., Williamson S.R., Rao Q., Lopez-Beltran A., Montironi R., Eble J.N., Grignon D.J., Idrees M.T., Emerson R.E., Zhou X.J., Zhang S., Baldridge L.A., Hahn N.M., Wang M., Koch M.O., Cheng L. Novel markers of squamous differentiation in the urinary bladder. Hum. Pathol. 2013; 44 (10): 1989–1997. DOI: 10.1016/j.humpath.2013.04.005.
32. Westenend P.J., Stoop J.A., Hendriks J.G. Human papillomaviruses 6/11, 16/18 and 31/33/51 are not associated with squamous cell carcinoma of the urinary bladder. BJU Int. 2001; 88 (3): 198–201. DOI: 10.1046/j.1464-410x.2001.02230.x.
33. Kim S.H., Joung J.Y., Chung J., Park W.S., Lee K.H., Seo H.K. Detection of human papillomavirus infection and p16 immunohistochemistry expression in bladder cancer with squamous differentiation. PLoS One. 2014; 9 (3): e93525. DOI: 10.1371/journal.pone.0093525.
34. Javanmard B., Barghi M.R., Amani D., Fallah Karkan M., Mazloomfard M.M. Human papilloma virus DNA in tumor tissue and urine in different stage of bladder cancer. Urol. J. 2019; 16 (4): 352–356. DOI: 10.22037/uj.v0i0.4181.
35. Jørgensen K.R., Høyer S., Jakobsen J.K., Jensen T.K., Marcussen N., Wrist Lam G., Hasselager T., Thind P.O., Toft B.G., Steiniche T., Jensen J.B. Human papillomavirus and squa mous cell carcinoma of the urinary bladder: DaBlaCa-10 study. Scand. J. Urol. 2018; 52 (5-6): 371–376. DOI:10.1080/21681805.2018.1531920.
36. Mete U.K., Shenvi S., Singh M.P., Chakraborti A., Kakkar N., Ratho R.K., Mandal A.K. Human Papillomavirus in Urothelial Carcinoma of Bladder: An Indian study. Int. J. Appl. Basic Med. Res. 2018; 8 (4): 217–219. DOI: 10.4103/ijabmr.IJABMR_91_18.
37. Андабеков Т.Т. Влияние цитомегаловирусной инфекции на клиническое течение рака предстательной железы: дис. … канд. мед. наук. СПб., 2010: 98.
38. Лоран О.Б., Синякова Л.А., Гундорова Л.В., Косов В.А., Косова И.В., Колбасов Д.Н., Дольнов И.А., Кононков И.В., Кандинова Ю.В. Роль некоторых вирусов в канцерогенезе рака мочевого пузыря. Экспериментальная и клиническая урология. 2015; 3: 32–37.
39. Косова И.В., Лоран О.Б., Синякова Л.А. и др. Сочетанная вирусная инфекция при раке мочевого пузыря. Consilium Medicum. 2018; 20 (7): 30–36. DOI: 10.26442/2075-1753_2018.7.30-36.
Review
For citations:
Mikhaleva L.M., Kamalov A.A., Maryin G.G., Karpov V.K., Akopyan E.P., Osmanov O.A., Pechnikova V.V. The role of herpes and human papillomavirus infection in prostate and bladder carcinogenesis. Bulletin of Siberian Medicine. 2021;20(4):153-161. https://doi.org/10.20538/1682-0363-2021-4-153-161
Views:
1495
Email this article 